MoneyWorks4Me

Zydus Lifesciences informs about press release

25 Apr 2022 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated April 25, 2022 titled 'Zydus announces publication of ‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat in ‘American Journal of Nephrology’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1745.00
Dr. Reddys Labs. 1242.00
Cipla 1331.00
Lupin 1953.75
Zydus Lifesciences 1113.00
View more..